Certified by Founder Lodge
Longwood Fund
United States - Boston, MA
INVESTOR
1 Disclosed Funding Rounds $65,333,745
9 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Longwood creates and invests in science-based companies that develop novel solutions for important medical problems.
| Company | Date | Round | Raised |
|---|---|---|---|
 Newleos Therapeutics |
February, 20 ,2025 | Series A | $93,500,000 |
 Be Biopharma |
October, 23 ,2024 | Unknown | $82,000,000 |
 AAVantgarde Bio |
June, 07 ,2023 | Series A | $65,333,745 |
 Solu Therapeutics |
August, 01 ,2023 | Seed | $31,000,000 |
 Sitryx |
September, 28 ,2023 | Unknown | $39,500,000 |
 Tome Biosciences |
December, 14 ,2023 | Series B | $213,000,000 |
 Engrail Therapeutics |
March, 20 ,2024 | Series B | $157,000,000 |
| Be Biopharma |
October, 23 ,2024 | Unknown | $82,000,000 |
| Newleos Therapeutics |
February, 20 ,2025 | Series A | $93,500,000 |
Cherry Ventures
Blue Bear Capital
Slow Ventures
Climate Capital
Eniac Ventures
CRESS | $234,000 | (Feb 21, 2025)
Reverb Therapeutics | $21,000,000 | (Feb 21, 2025)
Safe Intelligence | $5,253,443 | (Feb 21, 2025)
EnPlusOne Biosciences | $10,000,000 | (Feb 21, 2025)
OpenEvidence | Undisclosed Amount | (Feb 21, 2025)
